Columbia University

Funding Organization

Awards Grant

  • A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV Prevention Behaviors in Diverse Adolescent MSM
  • A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA)
  • Aptamers-Based Arrays for Detection of Pathogenic IgA 1 O-Glycoforms in IgA Nephropathy
  • Automated Clinic Blood Pressure Assessment and Detection of White Coat and Masked Hypertension Study in African Americans
  • Blood Flow And Cognition In Asymptomatic Carotid Artery Disease
  • Carotid Revascularization And Medical Management For Asymptomatic Carotid Stenosis Trial-Hemodynamics (CREST-H)
  • Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)
  • Combined Cardiopulmonary Failure in COPD: SPIROMICS II - HF
  • Communities Designed to Support Cardiovascular Health for Older Adults
  • Depression, Biobehavioral Mechanisms, & CHD/Mortality Outcomes
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation
  • Extended Methods and Software Development for Health NLP
  • Genetic Contribution to Brain Arterial Dilatation and its Role in Cognition and Dementia
  • Genetics of IgA Nephropathy by Integrative Network-Based Association Studies
  • Impact of Social-Interpersonal Factors in the ER on PTSD/Cardiac Outcomes
  • Molecular Genetic Analysis of Human Obesity
  • NICHD Fetal Growth Twin Study Service Provider Agreement
  • Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)
  • Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes
  • Subclinical Interstitial Lung in MESA and FAR-ILD
  • Subclinical Interstitial Lung in MESA and FAR-ILD
  • Tau PET Imaging in Racially/Ethnically Diverse Middle-Aged Adults: Administrative Supplement (PA-18-591)
  • Trace Mineral Levels, Metabolomics, and Diabetes Risk
  • Trace Mineral Levels, The Trajectory of Cognitive Decline and Telomere Attrition
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer